Peer-reviewed veterinary case report
Risk factors for bladder bleeding in dogs with lymphoma
By Gaeta, R et al.·Published in Veterinary and comparative oncology·2014·Department of Clinical Studies, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Risk factors for development of sterile haemorrhagic cystitis in canine lymphoma patients receiving oral cyclophosphamide: a case-control study.
- Species:
- dog
Plain-English summary
A group of dogs with lymphoma being treated with oral cyclophosphamide developed sterile hemorrhagic cystitis (SHC), which is a painful bladder condition. The study found that older dogs and those receiving higher doses of cyclophosphamide were more likely to experience this issue. Interestingly, dogs on a specific shorter treatment protocol had a lower risk of developing SHC. Managing the dosage of cyclophosphamide carefully is important, as increasing the total amount given can significantly raise the chances of this bladder problem.
People also search for: dog lymphoma treatment side effects · sterile hemorrhagic cystitis in dogs · cyclophosphamide dosage for dogs
Abstract
Sterile haemorrhagic cystitis (SHC) is a known risk of cyclophosphamide treatment; however, most canine reports are case series. This case-control study examined risk factors for SHC in dogs with lymphoma receiving oral cyclophosphamide. Twenty-two dogs with SHC and 66 control dogs were identified. On univariate analysis, SHC risk factors included age (P = 0.041), induction protocol (P = 0.021) and cumulative cyclophosphamide dose (P = 0.002). On multivariate analysis, increasing cumulative cyclophosphamide dose was associated with increased risk of SHC and the 'short' induction protocol (protocol 1) was associated with decreased risk. Controlling for age and induction protocol, odds of SHC increased by 2.21 per 750 mg m(-2) increase in cyclophosphamide dose (P = 0.001). SHC from oral cyclophosphamide is a predominately delayed toxicity resulting from high cumulative doses.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23078083/